Description: CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Labcorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.

Description: Labcorp Holdings (LH) is drawing attention after its Plasma Detect assay was featured in two respected medical journals. The company’s digital pathology joint initiative with Lunit also made headlines at recent oncology conferences. See our latest analysis for Labcorp Holdings. Momentum has been building for Labcorp Holdings over 2025, with investor optimism fueled by advances in diagnostics and AI partnerships. The stock’s strong 1-year total shareholder return of 12.1% reflects both robust...

Description: Labcorp shares edge higher as new studies spotlight Plasma Detect's role in tracking MRD and improving post-surgery cancer detection.

Description: While Labcorp Holdings has underperformed the S&P 500 Index slightly over the past year, its YTD strength stands out. Analysts remain firmly bullish on the stock's growth potential.

Description: Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two recent peer-reviewed publications – Nature Medicine and Clinical Cancer Research.

Description: Lunit and Labcorp recently announced a collaboration to advance innovation in digital pathology and artificial intelligence for oncology research, leveraging Labcorp's clinical and pathology expertise alongside Lunit's AI algorithms. This partnership has already yielded research results presented at key scientific conferences, highlighting the potential of AI-driven spatial profiling to identify immune phenotypes in non-small cell lung cancer and guide precision immuno-oncology...

Description: Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

Description: The takeover extends a string of deals that have consolidated the outreach lab services market.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Labcorp Holdings Inc. ( NYSE:LH ) has announced that it will pay a dividend of $0.72 per share on the 11th of December...

Description: Even though Labcorp Holdings Inc. ( NYSE:LH ) posted strong earnings, investors appeared to be underwhelmed. We did...

Description: Labcorp’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively, reflecting investor concerns about profitability and future growth levers. Management attributed the quarter’s performance to robust organic growth in its Diagnostics segment—especially through increased demand for specialty and genetic testing platforms like Invitae. CEO Adam Schechter explained that "margin for the quarter improved 100 basis points, driven by Diagnostics," and highlight

Description: OLATHE, Kan., November 03, 2025--KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites i

Description: OPKO Health recently reported third-quarter earnings with revenue of US$151.67 million and net income of US$21.63 million, surpassing analyst expectations, and announced a collaboration with Regeneron Pharmaceuticals potentially valued at over US$1 billion. The company also finalized the US$225 million sale of its BioReference Health oncology assets to Labcorp and received FDA approval for broader use of its 4Kscore® Test, marking significant changes in its business focus and regulatory...

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Description: Labcorp Holdings Inc (LH) reports a robust 9% revenue increase and a 19% rise in adjusted EPS, while navigating challenges in early development and currency impacts.

Description: Labcorp Holdings (LH) posted a net profit margin of 6.2% for the period, up from 3.4% a year ago, as earnings surged 96.4% year-over-year. This is well above the company's five-year average despite a longer-term earnings decline of 30.6% per year. Shares sit at $248.14, notably below the estimated fair value of $557.86. The current price-to-earnings ratio of 24.1x is higher than peer and industry averages. Investors are eyeing a potential turnaround as earnings are forecast to grow 14% per...

Description: Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus estimates.

Description: Shares of healthcare diagnostics company Labcorp Holdings (NYSE:LH) fell 3.8% in the morning session after the company's third-quarter results, while beating headline estimates, revealed a miss on a key profitability metric and included guidance that failed to impress investors. The healthcare diagnostics company reported revenue of $3.56 billion, in line with Wall Street expectations, and an adjusted profit of $4.18 per share, which was 1% above consensus. However, investors looked past the top

Description: Labcorp's Q3 earnings beat forecasts and margins improve, but a trimmed 2025 sales outlook sends shares down.

Description: Margin for the quarter improved 100 basis points, driven by Diagnostics. Adjusted EPS grew 19%, and we generated strong free cash flow of $281 million. Moving to our business segments, Diagnostics revenue increased 8.5%, primarily due to strong organic growth of 6%.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: While the top- and bottom-line numbers for Labcorp (LH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus estimates.

Description: Labcorp (LH) delivered earnings and revenue surprises of +1.21% and -0.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Labcorp Holdings Inc. ( NYSE:LH ) will pay a dividend of $0.72 on the 11th of December. This payment means the dividend...

Description: The Burlington, North Carolina-based company said it had profit of $3.12 per share. Earnings, adjusted for one-time gains and costs, came to $4.18 per share. The results surpassed Wall Street expectations.

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2025 and updated full-year guidance.

Description: Healthcare diagnostics company Labcorp Holdings (NYSE:LH) will be reporting results this Tuesday before market open. Here’s what to look for.

Description: Labcorp announced it will begin offering the Elecsys pTau181 blood test nationwide by early 2026, making available the only FDA-cleared blood test in the U.S. to aid in the initial assessment for Alzheimer’s disease and cognitive decline in primary-care settings. This marks a significant step forward in expanding access to less invasive neurological diagnostics, helping streamline the testing process for an estimated 7.2 million Americans living with Alzheimer’s disease. We’ll now explore...

Description: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics, Labcorp plans to make the test available nationwide by early 2026.

Description: We came across a bullish thesis on Quest Diagnostics Incorporated on Quality Value Investing’s Substack by David J. Waldron. In this article, we will summarize the bulls’ thesis on DGX. Quest Diagnostics Incorporated’s share was trading at $185.39 as of October 14th. DGX’s trailing and forward P/E were 21.67 and 17.12 respectively according to Yahoo Finance. Quest […]

Description: Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Opportunities in the global fertility test market include rising demand due to lifestyle changes, delayed pregnancies, and increasing infertility rates. Growing awareness and acceptance of fertility testing, alongside the prevalence of reproductive disorders, also drive market expansion across diverse demographics globally. Fertility Test Market Fertility Test Market Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Fertility Test Market Size, Share & Trends Analysis Report by Test Type (Ovulation

Description: Labcorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.

Description: LH vs. DHR: Which Stock Is the Better Value Option?

Description: CHICAGO, October 20, 2025--A streamlined digital experience improved lab order adherence, reduced no-shows, and enhanced operational efficiency at Providence.

Description: Labcorp Holdings (LH) shares inched up about 1% today, adding to their steady gains over the past month. With recent momentum continuing, investors are considering what factors could drive further moves in the healthcare giant’s stock. See our latest analysis for Labcorp Holdings. Labcorp Holdings has delivered a robust run this year, with the share price rallying more than 25% year to date and momentum accelerating over the past quarter. Investors have seen an impressive 34% total...

Description: While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".